WeTrials
Recruiting

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

What is this study?

This clinical trial is testing an experimental drug called MCLA-158, both on its own and combined with other cancer treatments like chemotherapy or immunotherapy. The goal is to see how safe this new drug is and how well it works against advanced solid tumors, such as colorectal and head and neck cancers.

Who can participate?

You may be able to join if you have an advanced cancer that has spread and standard treatments have not worked. Participants need to be in generally good physical health and willing to provide tumor tissue samples and undergo regular imaging scans.

What will happen?

You will receive the study medication, which may be MCLA-158 alone or paired with other treatments, while doctors closely monitor your health and safety. This involves regular check-ups, scans to measure your tumor, and providing tissue samples if it is safe to do so.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in La Jolla, Los Angeles, and San Diego, California. Your care team will guide you through the exact schedule and location details.

Key Points
  • 1Tests the experimental cancer drug MCLA-158 alone and with other therapies
  • 2Open to patients with advanced solid tumors like colorectal and head and neck cancers
  • 3Currently recruiting at locations in California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced/Metastatic Solid TumorsColorectal CancerGastric CancerGastroesophageal-junction CancerNSCLCHNSCCHead and Neck Squamous Cell CarcinomaEsophageal Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.